- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 27
- States / cities
- Montgomery, Alabama • Little Rock, Arkansas • Burbank, California + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 20,860
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer's Disease
- Interventions
- Rifaximin 550 milligrams (MG)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Endometrioma
- Interventions
- Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Type 1 Diabetes
- Interventions
- Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks, No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
- Combination Product · Device
- Lead sponsor
- Ananda Basu, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Stroke
- Interventions
- Telerehabilitation Therapy, In-Clinic Therapy
- Device · Behavioral
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Irvine, California • San Diego, California • Jacksonville, Florida + 9 more
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Biopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy, Irinotecan, Leucovorin, Mitomycin, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Device + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- Duarte, California • Jacksonville, Florida • Greenlawn, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
- Interventions
- PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 15
- States / cities
- Huntsville, Alabama • Stanford, California • Athens, Georgia + 7 more
- Conditions
- Hematologic Malignancies
- Interventions
- SLS009, venetoclax, azacitidine
- Drug
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more
- Conditions
- Fat Pad Atrophy, Pain
- Interventions
- Ultrasound of the foot, Pedobarograph Measurements, Manchester Foot Pain and Disability Index
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Spinal Cord Injuries
- Interventions
- Daily acute intermittent hypoxia, Room air (SHAM), Walking + tSTIM, Walking + Sham transcutaneous spinal stimulation (tSHAM)
- Other
- Lead sponsor
- Spaulding Rehabilitation Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Cambridge, Massachusetts
- Conditions
- IUD Insertion Pain
- Interventions
- Ketorolac, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Hillsborough, North Carolina
- Conditions
- COVID-19
- Interventions
- ensovibep, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 27
- States / cities
- Jasper, Alabama • Colton, California • Fullerton, California + 21 more
- Conditions
- Chronic Pain
- Interventions
- Quantitative Sensory Testing (QST)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ankle Sprain
- Interventions
- Diclofenac epolamine, Placebo
- Drug · Other
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 658 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Carlsbad, California + 26 more
- Conditions
- Clavicle Fracture, Chest Injury
- Interventions
- Not listed
- Lead sponsor
- Anna Rockich
- Other
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Misinformation, Vaccine Hesitancy, Anxiety, Depression, COVID-19
- Interventions
- Attitudinal inoculation, Cognitive-behavioral therapy-informed intervention, Conventional public health messaging
- Behavioral
- Lead sponsor
- City University of New York, School of Public Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- PMS
- Interventions
- escitalopram, placebo
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 15 Years to 19 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOF
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- Lisa Satter
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • New York, New York • Houston, Texas
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Auranofin, Sirolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Carboplatin, Etoposide, Filgrastim, Ifosfamide, Leukapheresis, Plerixafor, Rituximab
- Drug · Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Coronary Artery Disease
- Interventions
- FFR-CT
- Diagnostic Test
- Lead sponsor
- HeartFlow, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Worcester, Massachusetts • Cleveland, Ohio
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemias, Multiple Myeloma With Plasmacytoma
- Interventions
- Single fraction radiation, Donor Lymphocyte Infusion (DLI), Apheresis
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostatic Neoplasms
- Interventions
- 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 20
- States / cities
- Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
- Conditions
- Occipital Neuralgia
- Interventions
- Device: Cryo-Touch III Study treatment at Day 0.
- Device
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Napa, California • Boise, Idaho • Overland Park, Kansas